您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > A-1331852
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
A-1331852
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
A-1331852图片
CAS NO:1430844-80-6
规格:≥98%
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议
500mg电议

产品介绍
理化性质和储存条件
Molecular Weight (MW)658.81
FormulaC38H38N6O3S
CAS No.1430844-80-6
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 100 mg/mL (151.8 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In vivo)NA
SynonymsA-1331852; A 1331852; A1331852
实验参考方法
In Vitro

In vitro activity: A-1331852 exhibits remarkable potency both as a single agent and in combination with TKIs in killing primary CD34+ CML cell. Also, It has remarkable potency in inducing apoptosis in these cells at low nanomolar concentrations as early as 1 h post-treatment


Cell Assay: Immunoprecipitation of BCL-XL is carried out in K562 cells, exposed to A-1331852 (100 nM) for 0-2 h, and the eluted complexes are immunoblotted for the indicated proteins. The input cell lysates and the immunodepleted supernatant (labeled as Flow-through) are immunoblotted to check the efficiency of the immunoprecipitation.

In VivoPrevious animal study found that A-1331852 could demonstrate antitumor efficacy in the Molt-4 xenograft model, such as tumor regressions as a single agent. In addition, in the NCI-H1963.FP5 xenograft model of SCLC, it was found that A-1331852 combined with venetoclax was able to recapitulate the efficacy of navitoclax
Animal modelSCID and SCID-bg mice
Formulation & DosageFormulated in 60% Phosal 50 PG, 27.5 % PEG 400, 10% ethanol, and 2.5% DMSO; 25 mg/kg; Oral gavage
References

Sci Transl Med. 2015 Mar 18;7(279):279ra40; Leukemia. 2016 Jun;30(6):1273-81.